RxDoctor Payments Data

Patrick McIntyre

Family · Montgomery, ALNPI 1407594369

Payments from drug & device makers

$3,283in general payments, 2019–2025

Across 144 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Boston Scientific$494
  • Sumitomo Pharma America, Inc.$365
  • Abbott$247
  • Astellas Pharma US Inc$140
  • Bayer$98
  • plus $699 from 15 others

What the payments were for

  • Travel & lodging$86126%
  • Food & beverage$2,42174%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,283 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$11,922
Medicare patients
83
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron69$41,093
MyrbetriqMirabegron55$28,938
Estradiol40$3,528
Tamsulosin Hcl141$1,997
Solifenacin Succinate11$518
Finasteride32$465
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$363
Levofloxacin24$256
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim66$225
Cephalexin60$193
Ciprofloxacin Hcl13$83
Fluconazole11$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$365$41,09369 claims
Astellas Pharma US IncMyrbetriq$140$28,93855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.

Other family in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →